Tech Company Financing Transactions
Alantos Pharmaceuticals Holding Funding Round
On 3/10/2005, Alantos Pharmaceuticals Holding announced $20 million in Series B financing from Earlybird Venture Capital, Oxford Bioscience Partners and SV Health Investors.
Transaction Overview
Company Name
Announced On
3/10/2005
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series B
Proceeds Purpose
Proceeds from the financing will be used to progress the Company's pipeline of compounds, particularly its two lead candidates for diabetes and osteoarthritis into clinical development.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
840 Memorial Dr. 2nd Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Not Recorded
Overview
Alantos Pharmaceuticals is a chemistry-driven discovery company with a proprietary pipeline of small molecule drugs focused in the area of inflammation and diabetes. Its two lead compounds are in pre-clinical development for Osteoarthritis and type II diabetes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Frank Douglas
Browse more venture capital transactions:
Prev: 3/10/2005: Quantum Leap Packaging venture capital transaction
Next: 3/11/2005: Novalar Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs